High Tech Pharm (A106190) 주식 개요는 전 세계적으로 카바페넴 기반 주사제 항생제를 연구, 개발, 제조 및 판매하는 회사입니다. 자세히 보기A106190 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적2/6재무 건전성6/6배당1/6강점공정 가치 추정치보다 낮은 67.2% 에서 거래위험 분석우리의 위험 점검에서 A106190에 대한 위험이 감지되지 않았습니다.모든 위험 점검 보기A106190 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩15.80k47.4% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-4b103b2016201920222025202620282031Revenue ₩66.9bEarnings ₩10.9bAdvancedSet Fair ValueView all narrativesHigh Tech Pharm Co., Ltd. 경쟁사Jeil PharmaceuticalLtdSymbol: KOSE:A271980Market cap: ₩191.2bSAMSUNG PHARMSymbol: KOSE:A001360Market cap: ₩151.0bJeil Pharma HoldingsSymbol: KOSE:A002620Market cap: ₩129.7bDaihan PharmaceuticalLtdSymbol: KOSDAQ:A023910Market cap: ₩161.1b가격 이력 및 성과High Tech Pharm 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₩15,800.0052주 최고가₩25,000.0052주 최저가₩10,700.00베타0.0551개월 변동-21.20%3개월 변동-2.29%1년 변동25.50%3년 변동83.58%5년 변동49.53%IPO 이후 변동71.74%최근 뉴스 및 업데이트Valuation Update With 7 Day Price Move • May 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩16,020, the stock trades at a trailing P/E ratio of 14.8x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 77% over the past three years.New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩19,340, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 137% over the past three years.공시 • Feb 24High Tech Pharm Co., Ltd., Annual General Meeting, Mar 20, 2026High Tech Pharm Co., Ltd., Annual General Meeting, Mar 20, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 28, daegeum-ro, eumseong-gun, chungcheongbuk-do, South Korea분석 기사 • Feb 10High Tech Pharm Co., Ltd. (KOSDAQ:106190) Stock Rockets 36% But Many Are Still Ignoring The CompanyHigh Tech Pharm Co., Ltd. ( KOSDAQ:106190 ) shareholders would be excited to see that the share price has had a great...Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩13,900, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 49% over the past three years.더 많은 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • May 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩16,020, the stock trades at a trailing P/E ratio of 14.8x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 77% over the past three years.New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩19,340, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 137% over the past three years.공시 • Feb 24High Tech Pharm Co., Ltd., Annual General Meeting, Mar 20, 2026High Tech Pharm Co., Ltd., Annual General Meeting, Mar 20, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 28, daegeum-ro, eumseong-gun, chungcheongbuk-do, South Korea분석 기사 • Feb 10High Tech Pharm Co., Ltd. (KOSDAQ:106190) Stock Rockets 36% But Many Are Still Ignoring The CompanyHigh Tech Pharm Co., Ltd. ( KOSDAQ:106190 ) shareholders would be excited to see that the share price has had a great...Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩13,900, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 49% over the past three years.분석 기사 • Sep 02Investor Optimism Abounds High Tech Pharm Co., Ltd. (KOSDAQ:106190) But Growth Is LackingIt's not a stretch to say that High Tech Pharm Co., Ltd.'s ( KOSDAQ:106190 ) price-to-earnings (or "P/E") ratio of...Buy Or Sell Opportunity • Jul 09Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.4% to ₩12,960. The fair value is estimated to be ₩16,323, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable.Buy Or Sell Opportunity • Jun 18Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 19% to ₩12,970. The fair value is estimated to be ₩16,323, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable.분석 기사 • Jun 11We Think High Tech Pharm (KOSDAQ:106190) Can Stay On Top Of Its DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...New Risk • Apr 02New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩144.1b (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.공시 • Feb 25High Tech Pharm Co., Ltd., Annual General Meeting, Mar 21, 2025High Tech Pharm Co., Ltd., Annual General Meeting, Mar 21, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 286, daegeum-ro, eumseong-gun, chungcheongbuk-do, chungju South KoreaUpcoming Dividend • Dec 20Upcoming dividend of ₩66.67 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 18 April 2025. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.1%).New Risk • Dec 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩142.8b (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.Reported Earnings • Nov 14Third quarter 2024 earnings released: EPS: ₩223 (vs ₩126 in 3Q 2023)Third quarter 2024 results: EPS: ₩223 (up from ₩126 in 3Q 2023). Revenue: ₩16.9b (down 10% from 3Q 2023). Net income: ₩2.37b (up 77% from 3Q 2023). Profit margin: 14% (up from 7.1% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.분석 기사 • Oct 23A Look At The Intrinsic Value Of High Tech Pharm Co., Ltd. (KOSDAQ:106190)Key Insights Using the 2 Stage Free Cash Flow to Equity, High Tech Pharm fair value estimate is ₩16,394 With ₩15,600...Buy Or Sell Opportunity • Sep 23Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 14% to ₩13,030. The fair value is estimated to be ₩16,394, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.0% over the last 3 years. Meanwhile, the company has become profitable.분석 기사 • Aug 06Is High Tech Pharm (KOSDAQ:106190) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Jul 02Subdued Growth No Barrier To High Tech Pharm Co., Ltd. (KOSDAQ:106190) With Shares Advancing 25%High Tech Pharm Co., Ltd. ( KOSDAQ:106190 ) shares have continued their recent momentum with a 25% gain in the last...Valuation Update With 7 Day Price Move • Jun 26Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩16,030, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 56% over the past three years.New Risk • Jun 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • May 21Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩15,130, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 18x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 49% over the past three years.분석 기사 • May 09There's Reason For Concern Over High Tech Pharm Co., Ltd.'s (KOSDAQ:106190) Massive 25% Price JumpHigh Tech Pharm Co., Ltd. ( KOSDAQ:106190 ) shares have continued their recent momentum with a 25% gain in the last...Valuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩12,200, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 5.8% over the past three years.분석 기사 • Apr 23Is High Tech Pharm (KOSDAQ:106190) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Upcoming Dividend • Dec 20Inaugural dividend of ₩70.00 per shareEligible shareholders must have bought the stock before 27 December 2023. Payment date: 19 April 2024. This is the first dividend for High Tech Pharm since going public. The average dividend yield among industry peers is 1.1%.Valuation Update With 7 Day Price Move • Sep 11Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩16,440, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 13% over the past three years.Upcoming Dividend • Dec 21Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.0%).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Dec 22Inaugural dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 20 April 2022. The company is not currently making a profit and is not cash flow positive. This is the first dividend for High Tech Pharm since going public. The average dividend yield among industry peers is 0.8%.Reported Earnings • Nov 05Third quarter 2021 earnings released: ₩8.00 loss per share (vs ₩89.00 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩15.3b (down 29% from 3Q 2020). Net loss: ₩55.7m (down 109% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.Reported Earnings • May 18First quarter 2021 earnings released: EPS ₩64.00 (vs ₩7.00 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩19.6b (up 35% from 1Q 2020). Net income: ₩454.8m (up ₩498.0m from 1Q 2020). Profit margin: 2.3% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.분석 기사 • Feb 23We Think High Tech Pharm (KOSDAQ:106190) Has A Fair Chunk Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Jan 19Did High Tech Pharm's (KOSDAQ:106190) Share Price Deserve to Gain 91%?These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do...Is New 90 Day High Low • Jan 14New 90-day high: ₩26,350The company is up 118% from its price of ₩12,100 on 16 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 17% over the same period.Is New 90 Day High Low • Dec 22New 90-day high: ₩20,150The company is up 63% from its price of ₩12,400 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 17% over the same period.분석 기사 • Dec 15What Is The Ownership Structure Like For High Tech Pharm Co., Ltd. (KOSDAQ:106190)?The big shareholder groups in High Tech Pharm Co., Ltd. ( KOSDAQ:106190 ) have power over the company. Large companies...Is New 90 Day High Low • Dec 07New 90-day high: ₩15,200The company is up 27% from its price of ₩11,950 on 08 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period.Reported Earnings • Nov 15Third quarter 2020 earnings released: EPS ₩89.00The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: ₩21.5b (down 4.5% from 3Q 2019). Net income: ₩630.6m (up ₩1.71b from 3Q 2019). Profit margin: 2.9% (up from net loss in 3Q 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 110% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.주주 수익률A106190KR PharmaceuticalsKR 시장7D-0.5%-8.0%-2.5%1Y25.5%21.0%184.3%전체 주주 수익률 보기수익률 대 산업: A106190은 지난 1년 동안 21%의 수익을 기록한 KR Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: A106190은 지난 1년 동안 184.3%를 기록한 KR 시장보다 저조한 성과를 냈습니다.주가 변동성Is A106190's price volatile compared to industry and market?A106190 volatilityA106190 Average Weekly Movement12.0%Pharmaceuticals Industry Average Movement7.2%Market Average Movement9.3%10% most volatile stocks in KR Market16.5%10% least volatile stocks in KR Market4.9%안정적인 주가: A106190는 지난 3개월 동안 KR 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: A106190의 주간 변동성(12%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트1998n/aJeong-Soo Kimwww.htpharm.com하이테크팜은 카바페넴계 주사제 항생제를 연구, 개발, 제조 및 판매하는 글로벌 기업입니다. 이 회사는 1998년에 설립되었으며 대한민국 충주시에 본사를 두고 있습니다.더 보기High Tech Pharm Co., Ltd. 기초 지표 요약High Tech Pharm의 순이익과 매출은 시가총액과 어떻게 비교됩니까?A106190 기초 통계시가총액₩168.11b순이익 (TTM)₩11.48b매출 (TTM)₩70.18b14.6x주가수익비율(P/E)2.4x주가매출비율(P/S)A106190는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표A106190 손익계산서 (TTM)매출₩70.18b매출원가₩53.25b총이익₩16.94b기타 비용₩5.46b순이익₩11.48b최근 보고된 실적Dec 31, 2025다음 실적 발표일해당 없음주당순이익(EPS)1.08k총이익률24.13%순이익률16.35%부채/자본 비율0%A106190의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당0.9%현재 배당 수익률n/a배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 08:46종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스High Tech Pharm Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Valuation Update With 7 Day Price Move • May 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩16,020, the stock trades at a trailing P/E ratio of 14.8x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 77% over the past three years.
New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩19,340, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 137% over the past three years.
공시 • Feb 24High Tech Pharm Co., Ltd., Annual General Meeting, Mar 20, 2026High Tech Pharm Co., Ltd., Annual General Meeting, Mar 20, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 28, daegeum-ro, eumseong-gun, chungcheongbuk-do, South Korea
분석 기사 • Feb 10High Tech Pharm Co., Ltd. (KOSDAQ:106190) Stock Rockets 36% But Many Are Still Ignoring The CompanyHigh Tech Pharm Co., Ltd. ( KOSDAQ:106190 ) shareholders would be excited to see that the share price has had a great...
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩13,900, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 49% over the past three years.
Valuation Update With 7 Day Price Move • May 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩16,020, the stock trades at a trailing P/E ratio of 14.8x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 77% over the past three years.
New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩19,340, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 137% over the past three years.
공시 • Feb 24High Tech Pharm Co., Ltd., Annual General Meeting, Mar 20, 2026High Tech Pharm Co., Ltd., Annual General Meeting, Mar 20, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 28, daegeum-ro, eumseong-gun, chungcheongbuk-do, South Korea
분석 기사 • Feb 10High Tech Pharm Co., Ltd. (KOSDAQ:106190) Stock Rockets 36% But Many Are Still Ignoring The CompanyHigh Tech Pharm Co., Ltd. ( KOSDAQ:106190 ) shareholders would be excited to see that the share price has had a great...
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩13,900, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 49% over the past three years.
분석 기사 • Sep 02Investor Optimism Abounds High Tech Pharm Co., Ltd. (KOSDAQ:106190) But Growth Is LackingIt's not a stretch to say that High Tech Pharm Co., Ltd.'s ( KOSDAQ:106190 ) price-to-earnings (or "P/E") ratio of...
Buy Or Sell Opportunity • Jul 09Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.4% to ₩12,960. The fair value is estimated to be ₩16,323, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable.
Buy Or Sell Opportunity • Jun 18Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 19% to ₩12,970. The fair value is estimated to be ₩16,323, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable.
분석 기사 • Jun 11We Think High Tech Pharm (KOSDAQ:106190) Can Stay On Top Of Its DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • Apr 02New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩144.1b (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
공시 • Feb 25High Tech Pharm Co., Ltd., Annual General Meeting, Mar 21, 2025High Tech Pharm Co., Ltd., Annual General Meeting, Mar 21, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 286, daegeum-ro, eumseong-gun, chungcheongbuk-do, chungju South Korea
Upcoming Dividend • Dec 20Upcoming dividend of ₩66.67 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 18 April 2025. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.1%).
New Risk • Dec 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩142.8b (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
Reported Earnings • Nov 14Third quarter 2024 earnings released: EPS: ₩223 (vs ₩126 in 3Q 2023)Third quarter 2024 results: EPS: ₩223 (up from ₩126 in 3Q 2023). Revenue: ₩16.9b (down 10% from 3Q 2023). Net income: ₩2.37b (up 77% from 3Q 2023). Profit margin: 14% (up from 7.1% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
분석 기사 • Oct 23A Look At The Intrinsic Value Of High Tech Pharm Co., Ltd. (KOSDAQ:106190)Key Insights Using the 2 Stage Free Cash Flow to Equity, High Tech Pharm fair value estimate is ₩16,394 With ₩15,600...
Buy Or Sell Opportunity • Sep 23Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 14% to ₩13,030. The fair value is estimated to be ₩16,394, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.0% over the last 3 years. Meanwhile, the company has become profitable.
분석 기사 • Aug 06Is High Tech Pharm (KOSDAQ:106190) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • Jul 02Subdued Growth No Barrier To High Tech Pharm Co., Ltd. (KOSDAQ:106190) With Shares Advancing 25%High Tech Pharm Co., Ltd. ( KOSDAQ:106190 ) shares have continued their recent momentum with a 25% gain in the last...
Valuation Update With 7 Day Price Move • Jun 26Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩16,030, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 56% over the past three years.
New Risk • Jun 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • May 21Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩15,130, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 18x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 49% over the past three years.
분석 기사 • May 09There's Reason For Concern Over High Tech Pharm Co., Ltd.'s (KOSDAQ:106190) Massive 25% Price JumpHigh Tech Pharm Co., Ltd. ( KOSDAQ:106190 ) shares have continued their recent momentum with a 25% gain in the last...
Valuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩12,200, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 5.8% over the past three years.
분석 기사 • Apr 23Is High Tech Pharm (KOSDAQ:106190) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Upcoming Dividend • Dec 20Inaugural dividend of ₩70.00 per shareEligible shareholders must have bought the stock before 27 December 2023. Payment date: 19 April 2024. This is the first dividend for High Tech Pharm since going public. The average dividend yield among industry peers is 1.1%.
Valuation Update With 7 Day Price Move • Sep 11Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩16,440, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 13% over the past three years.
Upcoming Dividend • Dec 21Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.0%).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Dec 22Inaugural dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 20 April 2022. The company is not currently making a profit and is not cash flow positive. This is the first dividend for High Tech Pharm since going public. The average dividend yield among industry peers is 0.8%.
Reported Earnings • Nov 05Third quarter 2021 earnings released: ₩8.00 loss per share (vs ₩89.00 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩15.3b (down 29% from 3Q 2020). Net loss: ₩55.7m (down 109% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 18First quarter 2021 earnings released: EPS ₩64.00 (vs ₩7.00 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩19.6b (up 35% from 1Q 2020). Net income: ₩454.8m (up ₩498.0m from 1Q 2020). Profit margin: 2.3% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.
분석 기사 • Feb 23We Think High Tech Pharm (KOSDAQ:106190) Has A Fair Chunk Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
분석 기사 • Jan 19Did High Tech Pharm's (KOSDAQ:106190) Share Price Deserve to Gain 91%?These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do...
Is New 90 Day High Low • Jan 14New 90-day high: ₩26,350The company is up 118% from its price of ₩12,100 on 16 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 17% over the same period.
Is New 90 Day High Low • Dec 22New 90-day high: ₩20,150The company is up 63% from its price of ₩12,400 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 17% over the same period.
분석 기사 • Dec 15What Is The Ownership Structure Like For High Tech Pharm Co., Ltd. (KOSDAQ:106190)?The big shareholder groups in High Tech Pharm Co., Ltd. ( KOSDAQ:106190 ) have power over the company. Large companies...
Is New 90 Day High Low • Dec 07New 90-day high: ₩15,200The company is up 27% from its price of ₩11,950 on 08 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period.
Reported Earnings • Nov 15Third quarter 2020 earnings released: EPS ₩89.00The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: ₩21.5b (down 4.5% from 3Q 2019). Net income: ₩630.6m (up ₩1.71b from 3Q 2019). Profit margin: 2.9% (up from net loss in 3Q 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 110% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
